Short answer
Protalix BioTherapeutics, Inc. (PLX) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $34M (up 233.7% year over year) with net income of $18M.
Q1 2026 key financials · XBRL
- Revenue
- $34M
- +233.7% YoY
- Net income
- $18M
- +606.1% YoY
- Operating margin
- 62.7%
- EPS (diluted)
- $0.22
- +540.0% YoY
Source: XBRL data from the Protalix BioTherapeutics, Inc. (PLX) Q1 2026 10-Q on SEC EDGAR. USD.
Protalix BioTherapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $33.750M, up from $10.113M YoY, driven by $25.0M Chiesi milestone payment
- Net income $18.317M vs $3.619M loss YoY; operating income $21.146M vs $4.145M loss
- Best product line Chiesi sales $3.513M vs $0; Pfizer sales worst at $1.452M, down $5.527M
- Cash, equivalents and short-term deposits $51.1M at March 31, 2026; no ATM sales versus $3.0M in 2025
- R&D expense $5.426M, up 56% YoY; management expects significant, increasing spending for RELEASE study and other trials
Risk Factors
- No material risk-factor changes from December 31, 2025 Form 10-K
- Executive retention exposure: Yaron Naos agreement includes $400,000 change-of-control bonus
- Employment-cost commitment: Naos monthly base salary 70,000 New Israeli Shekels
- Governance compliance: no directors or officers adopted or terminated Rule 10b5-1 arrangements during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protalix BioTherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.